HIV-associated neurocognitive disorder

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Authors: Edelstein H, Maruff P, Robertson K, Ross LL, Shaefer MS, Small CB, Wohl D

Journal: Journal of Neurovirology

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, […]

Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.

Authors: Bloch M, Brew BJ, Carberry A, Cysique LA, Kamminga J, Vincent T

Journal: Journal of Clinical and Experimental Neuropsychology

INTRODUCTION: The current study sought to determine the optimal impairment rating definition for a new HIV-associated neurocognitive disorder (HAND) screening procedure as compared to standard neuropsychological testing. METHOD: A total of 55 HIV-infected (HIV+; 19% AIDS; […]

Back to Publications